Comparing coverage of medically indicated reduction mammoplasty among Swiss health insurers: a retrospective study.
Abstract
[BACKGROUND] Reduction mammoplasty is commonly used to treat macromastia, highlighting the need to address the physical and psychosocial issues associated with breast hypertrophy. However, clear inconsistencies in insurance coverage and varying criteria for medically necessary surgery are evident. The compliance of Swiss insurance companies with the 2019 recommendations of the Swiss Society of Medical Officers and Insurance Physicians has not been fully assessed.
[AIM] This study aimed to investigate the proportion and variability in cost approvals for reduction mammoplasty among Swiss insurers, focusing on differences in their approval and denial rates.
[METHODS] A retrospective study was conducted on patients presenting with breast disease at Spital Thurgau AG between January 2016 and December 2022. It analysed the proportion and variability in cost approval rates for reduction mammoplasty among different insurance providers. Demographic patient data were collected and statistically analysed using chi-squared and Fisher's exact tests to evaluate if a statistically significant relationship exists between insurance providers and cost approval. Only Swiss insurance providers servicing at least five patients in the final cohort were included.
[RESULTS] Between January 2016 and December 2022, 1105 patients with breast disease were evaluated at Spital Thurgau AG, of whom 210 were eligible for this study on reduction mammoplasty cost approvals. Of the 210 cost approval requests made to nine different insurance companies, 54% were approved. Approval rates differed significantly among insurers (p = 0.003).
[CONCLUSION] This study uncovered an elevated rate of cost approval denials, which depended significantly on the insurance provider. To ensure that the costs of a medically indicated breast reduction are covered consistently and fairly, a review of existing guidelines and their implementation is necessary to improve the system.
[AIM] This study aimed to investigate the proportion and variability in cost approvals for reduction mammoplasty among Swiss insurers, focusing on differences in their approval and denial rates.
[METHODS] A retrospective study was conducted on patients presenting with breast disease at Spital Thurgau AG between January 2016 and December 2022. It analysed the proportion and variability in cost approval rates for reduction mammoplasty among different insurance providers. Demographic patient data were collected and statistically analysed using chi-squared and Fisher's exact tests to evaluate if a statistically significant relationship exists between insurance providers and cost approval. Only Swiss insurance providers servicing at least five patients in the final cohort were included.
[RESULTS] Between January 2016 and December 2022, 1105 patients with breast disease were evaluated at Spital Thurgau AG, of whom 210 were eligible for this study on reduction mammoplasty cost approvals. Of the 210 cost approval requests made to nine different insurance companies, 54% were approved. Approval rates differed significantly among insurers (p = 0.003).
[CONCLUSION] This study uncovered an elevated rate of cost approval denials, which depended significantly on the insurance provider. To ensure that the costs of a medically indicated breast reduction are covered consistently and fairly, a review of existing guidelines and their implementation is necessary to improve the system.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | reduction mammoplasty
|
유방성형술 | dict | 5 | |
| 해부 | breast
|
유방 | dict | 4 | |
| 시술 | breast reduction
|
유방성형술 | dict | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 질환 | macromastia
|
C0020565
Hypertrophy of Breast
|
scispacy | 1 | |
| 질환 | breast hypertrophy
|
C0020565
Hypertrophy of Breast
|
scispacy | 1 | |
| 질환 | breast disease
|
C0006145
Breast Diseases
|
scispacy | 1 | |
| 질환 | Swiss health
|
scispacy | 1 | ||
| 질환 | Swiss
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Humans; Retrospective Studies; Switzerland; Female; Mammaplasty; Insurance Coverage; Insurance, Health; Breast; Adult; Middle Aged; Hypertrophy; Insurance Carriers
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.